erlotinib has been researched along with osi 906 in 6 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (osi 906) | Trials (osi 906) | Recent Studies (post-2010) (osi 906) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 20 | 0 | 17 |
| Protein | Taxonomy | erlotinib (IC50) | osi 906 (IC50) |
|---|---|---|---|
| Insulin receptor | Homo sapiens (human) | 0.0483 | |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | 0.0165 | |
| Insulin receptor-related protein | Homo sapiens (human) | 0.048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bamaung, NY; Bell, RL; Clark, RF; Davidsen, SK; Erickson, SA; Fidanze, SD; Hubbard, RD; Johnson, EF; Kovar, P; Mantei, R; Pappano, WN; Sheppard, GS; Sorensen, BK; Stewart, KD; Swinger, KK; Tucker, LA; Wang, GT; Wang, J; Wilsbacher, JL; Zhang, Q | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Baska, F; Greff, Z; Gyulavári, P; Kéri, G; Kurkó, I; Orfi, L; Orfi, Z; Pénzes, K; Peták, I; Szántai-Kis, C; Szokol, B; Torka, R; Ullrich, A; Vántus, T | 1 |
| Bantscheff, M; Bergamini, G; Gohlke, B; Gupta, V; Handa, H; Heinzlmeir, S; Helm, D; Klaeger, S; Kuster, B; Médard, G; Perrin, J; Preissner, R; Qiao, H; Savitski, MM | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
6 other study(ies) available for erlotinib and osi 906
| Article | Year |
|---|---|
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
Topics: ErbB Receptors; Models, Molecular; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Thiazoles | 2010 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
Topics: | 2014 |
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
Topics: Benzocycloheptenes; Cell Line, Tumor; Ferrochelatase; Heme; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Proteomics; Pyrazines; Pyridines; Quinolines; Sulfonamides; Vemurafenib | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |